Trial Profile
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Dec 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Acronyms IMAGE
- Sponsors Bristol-Myers Squibb
- 22 Dec 2021 Status changed from active, no longer recruiting to completed.
- 10 Apr 2018 Planned End Date changed from 30 Mar 2020 to 28 Nov 2020.
- 10 Apr 2018 Planned primary completion date changed from 29 Mar 2018 to 11 May 2020.